Repotrectinib monotherapy (TRIDENT-1) — ROS1+ NSCLC (TKI-naive or post-prior ROS1-TKI)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-REPOTRECTINIB |
|---|
| ID | REG-REPOTRECTINIB-NSCLC |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ESMO-NSCLC-METASTATIC-2024 SRC-NCCN-NSCLC-2025 SRC-TRIDENT1-DRILON-2024 |
Notes
TRIDENT-1: ROS1 TKI-naive ORR 79% (mDOR 34.1 mo); post-1 ROS1-TKI ORR 38% incl. G2032R subset; intracranial ORR 89% TKI-naive. FDA approval 2023 for ROS1+ NSCLC any line. Lead-in dosing critical to manage CNS-AE — direct BID without ramp significantly worsens vestibular toxicity.
Used By
Indication
IND-NSCLC-2L-ROS1-REPOTRECTINIB- IND-NSCLC-2L-ROS1-REPOTRECTINIBIND-NSCLC-ROS1-1L-REPOTRECTINIB- IND-NSCLC-ROS1-1L-REPOTRECTINIBIND-PAN-NTRK-2L-REPOTRECTINIB- IND-PAN-NTRK-2L-REPOTRECTINIB
Regimen
REG-REPOTRECTINIB-NTRK-PAN-TUMOR- Repotrectinib monotherapy (TRIDENT-1) — NTRK-fusion+ solid tumors (pan-tumor, TKI-naive o...